nodes	percent_of_prediction	percent_of_DWPC	metapath
Vemurafenib—melanoma—sarcoma	0.295	0.518	CtDrD
Vemurafenib—skin cancer—sarcoma	0.274	0.482	CtDrD
Vemurafenib—ABCC1—Dactinomycin—sarcoma	0.0398	0.13	CbGbCtD
Vemurafenib—ABCC1—Mitoxantrone—sarcoma	0.0357	0.116	CbGbCtD
Vemurafenib—ABCC1—Epirubicin—sarcoma	0.0289	0.0938	CbGbCtD
Vemurafenib—ABCG2—Dactinomycin—sarcoma	0.0267	0.0867	CbGbCtD
Vemurafenib—ABCC1—Vincristine—sarcoma	0.0245	0.0798	CbGbCtD
Vemurafenib—ABCG2—Mitoxantrone—sarcoma	0.0239	0.0776	CbGbCtD
Vemurafenib—ABCC1—Etoposide—sarcoma	0.0225	0.0731	CbGbCtD
Vemurafenib—ABCG2—Vincristine—sarcoma	0.0164	0.0534	CbGbCtD
Vemurafenib—ABCC1—Doxorubicin—sarcoma	0.0153	0.0499	CbGbCtD
Vemurafenib—ABCG2—Etoposide—sarcoma	0.015	0.0489	CbGbCtD
Vemurafenib—CYP1A2—Dacarbazine—sarcoma	0.0127	0.0412	CbGbCtD
Vemurafenib—CYP3A4—Thiotepa—sarcoma	0.012	0.039	CbGbCtD
Vemurafenib—ABCG2—Doxorubicin—sarcoma	0.0103	0.0334	CbGbCtD
Vemurafenib—CYP1A2—Etoposide—sarcoma	0.00621	0.0202	CbGbCtD
Vemurafenib—CYP3A4—Mitoxantrone—sarcoma	0.00516	0.0168	CbGbCtD
Vemurafenib—CYP3A4—Vincristine—sarcoma	0.00355	0.0115	CbGbCtD
Vemurafenib—CYP2D6—Doxorubicin—sarcoma	0.00349	0.0113	CbGbCtD
Vemurafenib—CYP3A4—Etoposide—sarcoma	0.00325	0.0106	CbGbCtD
Vemurafenib—CYP3A4—Doxorubicin—sarcoma	0.00222	0.00721	CbGbCtD
Vemurafenib—RAF1—myometrium—sarcoma	0.000592	0.0422	CbGeAlD
Vemurafenib—BRAF—uterus—sarcoma	0.000576	0.041	CbGeAlD
Vemurafenib—RAF1—embryo—sarcoma	0.000569	0.0406	CbGeAlD
Vemurafenib—RAF1—seminal vesicle—sarcoma	0.000535	0.0381	CbGeAlD
Vemurafenib—RAF1—hematopoietic system—sarcoma	0.000508	0.0362	CbGeAlD
Vemurafenib—ALB—mammary gland—sarcoma	0.000505	0.036	CbGeAlD
Vemurafenib—BRAF—tendon—sarcoma	0.000505	0.036	CbGeAlD
Vemurafenib—RAF1—connective tissue—sarcoma	0.000489	0.0349	CbGeAlD
Vemurafenib—BRAF—bone marrow—sarcoma	0.000489	0.0348	CbGeAlD
Vemurafenib—RAF1—smooth muscle tissue—sarcoma	0.000448	0.0319	CbGeAlD
Vemurafenib—RAF1—skin of body—sarcoma	0.000442	0.0315	CbGeAlD
Vemurafenib—BRAF—testis—sarcoma	0.000418	0.0298	CbGeAlD
Vemurafenib—BRAF—liver—sarcoma	0.000395	0.0282	CbGeAlD
Vemurafenib—RAF1—cardiac atrium—sarcoma	0.000386	0.0275	CbGeAlD
Vemurafenib—RAF1—uterus—sarcoma	0.000384	0.0273	CbGeAlD
Vemurafenib—RAF1—lymphoid tissue—sarcoma	0.000358	0.0255	CbGeAlD
Vemurafenib—ORM1—hematopoietic system—sarcoma	0.000351	0.025	CbGeAlD
Vemurafenib—RAF1—tendon—sarcoma	0.000336	0.024	CbGeAlD
Vemurafenib—RAF1—bone marrow—sarcoma	0.000326	0.0232	CbGeAlD
Vemurafenib—BRAF—lymph node—sarcoma	0.000303	0.0216	CbGeAlD
Vemurafenib—ABCC1—myometrium—sarcoma	0.000296	0.0211	CbGeAlD
Vemurafenib—RAF1—testis—sarcoma	0.000279	0.0198	CbGeAlD
Vemurafenib—ABCC1—seminal vesicle—sarcoma	0.000267	0.019	CbGeAlD
Vemurafenib—RAF1—liver—sarcoma	0.000263	0.0188	CbGeAlD
Vemurafenib—ABCG2—myometrium—sarcoma	0.000245	0.0174	CbGeAlD
Vemurafenib—Cyst—Doxorubicin—sarcoma	0.000232	0.00621	CcSEcCtD
Vemurafenib—Stevens-Johnson syndrome—Dactinomycin—sarcoma	0.000229	0.00613	CcSEcCtD
Vemurafenib—ORM1—bone marrow—sarcoma	0.000225	0.016	CbGeAlD
Vemurafenib—Paralysis—Doxorubicin—sarcoma	0.000224	0.00597	CcSEcCtD
Vemurafenib—ABCG2—seminal vesicle—sarcoma	0.000221	0.0158	CbGeAlD
Vemurafenib—Photosensitivity reaction—Vincristine—sarcoma	0.000212	0.00566	CcSEcCtD
Vemurafenib—Weight decreased—Vincristine—sarcoma	0.00021	0.00561	CcSEcCtD
Vemurafenib—Connective tissue disorder—Thiotepa—sarcoma	0.000206	0.0055	CcSEcCtD
Vemurafenib—Rigors—Epirubicin—sarcoma	0.000206	0.00549	CcSEcCtD
Vemurafenib—Weight decreased—Mitoxantrone—sarcoma	0.000204	0.00546	CcSEcCtD
Vemurafenib—Neuropathy peripheral—Vincristine—sarcoma	0.000203	0.00542	CcSEcCtD
Vemurafenib—CYP1A2—hematopoietic system—sarcoma	0.000202	0.0144	CbGeAlD
Vemurafenib—RAF1—lymph node—sarcoma	0.000202	0.0144	CbGeAlD
Vemurafenib—Neoplasm malignant—Epirubicin—sarcoma	0.000197	0.00525	CcSEcCtD
Vemurafenib—Erythema multiforme—Dactinomycin—sarcoma	0.000196	0.00525	CcSEcCtD
Vemurafenib—Toxic epidermal necrolysis—Etoposide—sarcoma	0.000196	0.00523	CcSEcCtD
Vemurafenib—Eye disorder—Thiotepa—sarcoma	0.000196	0.00523	CcSEcCtD
Vemurafenib—Cardiac disorder—Thiotepa—sarcoma	0.000194	0.00519	CcSEcCtD
Vemurafenib—ABCC1—cardiac atrium—sarcoma	0.000193	0.0137	CbGeAlD
Vemurafenib—ABCC1—uterus—sarcoma	0.000192	0.0137	CbGeAlD
Vemurafenib—Rigors—Doxorubicin—sarcoma	0.00019	0.00508	CcSEcCtD
Vemurafenib—Angiopathy—Thiotepa—sarcoma	0.00019	0.00507	CcSEcCtD
Vemurafenib—Mediastinal disorder—Thiotepa—sarcoma	0.000189	0.00504	CcSEcCtD
Vemurafenib—Chills—Thiotepa—sarcoma	0.000188	0.00502	CcSEcCtD
Vemurafenib—Chills—Dactinomycin—sarcoma	0.000186	0.00498	CcSEcCtD
Vemurafenib—Alopecia—Thiotepa—sarcoma	0.000185	0.00494	CcSEcCtD
Vemurafenib—Alopecia—Dactinomycin—sarcoma	0.000184	0.00491	CcSEcCtD
Vemurafenib—Connective tissue disorder—Vincristine—sarcoma	0.000182	0.00487	CcSEcCtD
Vemurafenib—Malnutrition—Thiotepa—sarcoma	0.000182	0.00487	CcSEcCtD
Vemurafenib—Erythema—Thiotepa—sarcoma	0.000182	0.00487	CcSEcCtD
Vemurafenib—Neoplasm malignant—Doxorubicin—sarcoma	0.000182	0.00486	CcSEcCtD
Vemurafenib—ORM1—liver—sarcoma	0.000182	0.0129	CbGeAlD
Vemurafenib—Erythema—Dactinomycin—sarcoma	0.000181	0.00483	CcSEcCtD
Vemurafenib—Back pain—Thiotepa—sarcoma	0.000176	0.00471	CcSEcCtD
Vemurafenib—Cardiac disorder—Vincristine—sarcoma	0.000172	0.0046	CcSEcCtD
Vemurafenib—Musculoskeletal pain—Epirubicin—sarcoma	0.00017	0.00454	CcSEcCtD
Vemurafenib—ALB—testis—sarcoma	0.000169	0.012	CbGeAlD
Vemurafenib—Angiopathy—Vincristine—sarcoma	0.000168	0.0045	CcSEcCtD
Vemurafenib—ABCC1—tendon—sarcoma	0.000168	0.012	CbGeAlD
Vemurafenib—Infestation—Etoposide—sarcoma	0.000168	0.00448	CcSEcCtD
Vemurafenib—Infestation NOS—Etoposide—sarcoma	0.000168	0.00448	CcSEcCtD
Vemurafenib—Mediastinal disorder—Vincristine—sarcoma	0.000167	0.00447	CcSEcCtD
Vemurafenib—Stevens-Johnson syndrome—Etoposide—sarcoma	0.000166	0.00444	CcSEcCtD
Vemurafenib—Neuropathy peripheral—Etoposide—sarcoma	0.000164	0.00439	CcSEcCtD
Vemurafenib—Alopecia—Vincristine—sarcoma	0.000164	0.00438	CcSEcCtD
Vemurafenib—Chills—Mitoxantrone—sarcoma	0.000162	0.00433	CcSEcCtD
Vemurafenib—Alopecia—Mitoxantrone—sarcoma	0.00016	0.00427	CcSEcCtD
Vemurafenib—ALB—liver—sarcoma	0.000159	0.0114	CbGeAlD
Vemurafenib—Cough—Thiotepa—sarcoma	0.000159	0.00425	CcSEcCtD
Vemurafenib—ABCG2—uterus—sarcoma	0.000159	0.0113	CbGeAlD
Vemurafenib—Erythema—Mitoxantrone—sarcoma	0.000157	0.0042	CcSEcCtD
Vemurafenib—Musculoskeletal pain—Doxorubicin—sarcoma	0.000157	0.0042	CcSEcCtD
Vemurafenib—Back pain—Vincristine—sarcoma	0.000156	0.00418	CcSEcCtD
Vemurafenib—Arthralgia—Thiotepa—sarcoma	0.000155	0.00415	CcSEcCtD
Vemurafenib—Myalgia—Thiotepa—sarcoma	0.000155	0.00415	CcSEcCtD
Vemurafenib—Dysgeusia—Mitoxantrone—sarcoma	0.000154	0.00412	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Thiotepa—sarcoma	0.000154	0.00412	CcSEcCtD
Vemurafenib—Myalgia—Dactinomycin—sarcoma	0.000154	0.00411	CcSEcCtD
Vemurafenib—Rash maculo-papular—Epirubicin—sarcoma	0.000153	0.00408	CcSEcCtD
Vemurafenib—Back pain—Mitoxantrone—sarcoma	0.000152	0.00407	CcSEcCtD
Vemurafenib—Neoplasm—Epirubicin—sarcoma	0.000152	0.00405	CcSEcCtD
Vemurafenib—Infection—Thiotepa—sarcoma	0.000148	0.00395	CcSEcCtD
Vemurafenib—Infection—Dactinomycin—sarcoma	0.000147	0.00392	CcSEcCtD
Vemurafenib—CYP3A4—hematopoietic system—sarcoma	0.000146	0.0104	CbGeAlD
Vemurafenib—Nervous system disorder—Thiotepa—sarcoma	0.000146	0.0039	CcSEcCtD
Vemurafenib—Skin disorder—Thiotepa—sarcoma	0.000144	0.00386	CcSEcCtD
Vemurafenib—CYP2D6—hematopoietic system—sarcoma	0.000144	0.0103	CbGeAlD
Vemurafenib—Erythema multiforme—Etoposide—sarcoma	0.000142	0.0038	CcSEcCtD
Vemurafenib—Rash maculo-papular—Doxorubicin—sarcoma	0.000141	0.00377	CcSEcCtD
Vemurafenib—Eye disorder—Etoposide—sarcoma	0.000141	0.00375	CcSEcCtD
Vemurafenib—Neoplasm—Doxorubicin—sarcoma	0.00014	0.00375	CcSEcCtD
Vemurafenib—Cardiac disorder—Etoposide—sarcoma	0.00014	0.00373	CcSEcCtD
Vemurafenib—ORM1—lymph node—sarcoma	0.000139	0.00993	CbGeAlD
Vemurafenib—ABCC1—testis—sarcoma	0.000139	0.00991	CbGeAlD
Vemurafenib—Photosensitivity—Epirubicin—sarcoma	0.000139	0.00371	CcSEcCtD
Vemurafenib—Myalgia—Vincristine—sarcoma	0.000138	0.00368	CcSEcCtD
Vemurafenib—Cough—Mitoxantrone—sarcoma	0.000137	0.00367	CcSEcCtD
Vemurafenib—Angiopathy—Etoposide—sarcoma	0.000136	0.00365	CcSEcCtD
Vemurafenib—Mediastinal disorder—Etoposide—sarcoma	0.000136	0.00362	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Thiotepa—sarcoma	0.000135	0.00362	CcSEcCtD
Vemurafenib—Chills—Etoposide—sarcoma	0.000135	0.00361	CcSEcCtD
Vemurafenib—ABCG2—bone marrow—sarcoma	0.000135	0.0096	CbGeAlD
Vemurafenib—Musculoskeletal discomfort—Dactinomycin—sarcoma	0.000134	0.00359	CcSEcCtD
Vemurafenib—Myalgia—Mitoxantrone—sarcoma	0.000134	0.00358	CcSEcCtD
Vemurafenib—Arthralgia—Mitoxantrone—sarcoma	0.000134	0.00358	CcSEcCtD
Vemurafenib—Alopecia—Etoposide—sarcoma	0.000133	0.00355	CcSEcCtD
Vemurafenib—Anaphylactic shock—Vincristine—sarcoma	0.000132	0.00352	CcSEcCtD
Vemurafenib—ABCC1—liver—sarcoma	0.000132	0.00937	CbGeAlD
Vemurafenib—Infection—Vincristine—sarcoma	0.000131	0.0035	CcSEcCtD
Vemurafenib—Nervous system disorder—Vincristine—sarcoma	0.000129	0.00346	CcSEcCtD
Vemurafenib—Decreased appetite—Thiotepa—sarcoma	0.000129	0.00345	CcSEcCtD
Vemurafenib—Anaphylactic shock—Mitoxantrone—sarcoma	0.000128	0.00343	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Thiotepa—sarcoma	0.000128	0.00343	CcSEcCtD
Vemurafenib—Photosensitivity—Doxorubicin—sarcoma	0.000128	0.00343	CcSEcCtD
Vemurafenib—Decreased appetite—Dactinomycin—sarcoma	0.000128	0.00343	CcSEcCtD
Vemurafenib—Fatigue—Thiotepa—sarcoma	0.000128	0.00343	CcSEcCtD
Vemurafenib—Dysgeusia—Etoposide—sarcoma	0.000128	0.00343	CcSEcCtD
Vemurafenib—Infection—Mitoxantrone—sarcoma	0.000128	0.00341	CcSEcCtD
Vemurafenib—Fatigue—Dactinomycin—sarcoma	0.000127	0.0034	CcSEcCtD
Vemurafenib—Constipation—Thiotepa—sarcoma	0.000127	0.0034	CcSEcCtD
Vemurafenib—Back pain—Etoposide—sarcoma	0.000127	0.00338	CcSEcCtD
Vemurafenib—Skin disorder—Mitoxantrone—sarcoma	0.000125	0.00333	CcSEcCtD
Vemurafenib—Hypotension—Vincristine—sarcoma	0.000123	0.00329	CcSEcCtD
Vemurafenib—ALB—lymph node—sarcoma	0.000122	0.00871	CbGeAlD
Vemurafenib—Pain in extremity—Epirubicin—sarcoma	0.000122	0.00326	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Vincristine—sarcoma	0.00012	0.00321	CcSEcCtD
Vemurafenib—Hypotension—Mitoxantrone—sarcoma	0.00012	0.00321	CcSEcCtD
Vemurafenib—Body temperature increased—Thiotepa—sarcoma	0.000118	0.00314	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Mitoxantrone—sarcoma	0.000117	0.00313	CcSEcCtD
Vemurafenib—Body temperature increased—Dactinomycin—sarcoma	0.000117	0.00312	CcSEcCtD
Vemurafenib—ABCG2—testis—sarcoma	0.000115	0.00821	CbGeAlD
Vemurafenib—Decreased appetite—Vincristine—sarcoma	0.000115	0.00306	CcSEcCtD
Vemurafenib—Cough—Etoposide—sarcoma	0.000114	0.00305	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Vincristine—sarcoma	0.000114	0.00304	CcSEcCtD
Vemurafenib—Fatigue—Vincristine—sarcoma	0.000114	0.00304	CcSEcCtD
Vemurafenib—Constipation—Vincristine—sarcoma	0.000113	0.00301	CcSEcCtD
Vemurafenib—Pain in extremity—Doxorubicin—sarcoma	0.000113	0.00301	CcSEcCtD
Vemurafenib—Dry skin—Epirubicin—sarcoma	0.000112	0.00298	CcSEcCtD
Vemurafenib—Decreased appetite—Mitoxantrone—sarcoma	0.000112	0.00298	CcSEcCtD
Vemurafenib—Fatigue—Mitoxantrone—sarcoma	0.000111	0.00296	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—sarcoma	0.000111	0.00296	CcSEcCtD
Vemurafenib—Constipation—Mitoxantrone—sarcoma	0.00011	0.00293	CcSEcCtD
Vemurafenib—Toxic epidermal necrolysis—Epirubicin—sarcoma	0.00011	0.00293	CcSEcCtD
Vemurafenib—Hypersensitivity—Thiotepa—sarcoma	0.00011	0.00293	CcSEcCtD
Vemurafenib—ABCG2—liver—sarcoma	0.000109	0.00776	CbGeAlD
Vemurafenib—Hypersensitivity—Dactinomycin—sarcoma	0.000109	0.00291	CcSEcCtD
Vemurafenib—Anaphylactic shock—Etoposide—sarcoma	0.000107	0.00285	CcSEcCtD
Vemurafenib—Asthenia—Thiotepa—sarcoma	0.000107	0.00285	CcSEcCtD
Vemurafenib—Infection—Etoposide—sarcoma	0.000106	0.00284	CcSEcCtD
Vemurafenib—Asthenia—Dactinomycin—sarcoma	0.000106	0.00283	CcSEcCtD
Vemurafenib—Pruritus—Thiotepa—sarcoma	0.000105	0.00281	CcSEcCtD
Vemurafenib—CYP1A2—liver—sarcoma	0.000105	0.00747	CbGeAlD
Vemurafenib—Eosinophilia—Epirubicin—sarcoma	0.000104	0.00279	CcSEcCtD
Vemurafenib—Body temperature increased—Vincristine—sarcoma	0.000104	0.00279	CcSEcCtD
Vemurafenib—Skin disorder—Etoposide—sarcoma	0.000104	0.00277	CcSEcCtD
Vemurafenib—Dry skin—Doxorubicin—sarcoma	0.000103	0.00276	CcSEcCtD
Vemurafenib—Diarrhoea—Thiotepa—sarcoma	0.000102	0.00272	CcSEcCtD
Vemurafenib—Body temperature increased—Mitoxantrone—sarcoma	0.000102	0.00271	CcSEcCtD
Vemurafenib—Toxic epidermal necrolysis—Doxorubicin—sarcoma	0.000102	0.00271	CcSEcCtD
Vemurafenib—Diarrhoea—Dactinomycin—sarcoma	0.000101	0.0027	CcSEcCtD
Vemurafenib—ABCC1—lymph node—sarcoma	0.000101	0.00719	CbGeAlD
Vemurafenib—Hypotension—Etoposide—sarcoma	9.98e-05	0.00267	CcSEcCtD
Vemurafenib—Dizziness—Thiotepa—sarcoma	9.83e-05	0.00263	CcSEcCtD
Vemurafenib—Hypersensitivity—Vincristine—sarcoma	9.72e-05	0.0026	CcSEcCtD
Vemurafenib—Eosinophilia—Doxorubicin—sarcoma	9.65e-05	0.00258	CcSEcCtD
Vemurafenib—Photosensitivity reaction—Epirubicin—sarcoma	9.61e-05	0.00257	CcSEcCtD
Vemurafenib—Weight decreased—Epirubicin—sarcoma	9.53e-05	0.00255	CcSEcCtD
Vemurafenib—Hypersensitivity—Mitoxantrone—sarcoma	9.46e-05	0.00253	CcSEcCtD
Vemurafenib—Asthenia—Vincristine—sarcoma	9.46e-05	0.00253	CcSEcCtD
Vemurafenib—Vomiting—Thiotepa—sarcoma	9.46e-05	0.00253	CcSEcCtD
Vemurafenib—Infestation NOS—Epirubicin—sarcoma	9.39e-05	0.00251	CcSEcCtD
Vemurafenib—Infestation—Epirubicin—sarcoma	9.39e-05	0.00251	CcSEcCtD
Vemurafenib—Vomiting—Dactinomycin—sarcoma	9.39e-05	0.00251	CcSEcCtD
Vemurafenib—Rash—Thiotepa—sarcoma	9.38e-05	0.00251	CcSEcCtD
Vemurafenib—Dermatitis—Thiotepa—sarcoma	9.37e-05	0.0025	CcSEcCtD
Vemurafenib—Headache—Thiotepa—sarcoma	9.32e-05	0.00249	CcSEcCtD
Vemurafenib—Stevens-Johnson syndrome—Epirubicin—sarcoma	9.31e-05	0.00249	CcSEcCtD
Vemurafenib—Rash—Dactinomycin—sarcoma	9.31e-05	0.00249	CcSEcCtD
Vemurafenib—Decreased appetite—Etoposide—sarcoma	9.29e-05	0.00248	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Etoposide—sarcoma	9.22e-05	0.00246	CcSEcCtD
Vemurafenib—Asthenia—Mitoxantrone—sarcoma	9.21e-05	0.00246	CcSEcCtD
Vemurafenib—Fatigue—Etoposide—sarcoma	9.21e-05	0.00246	CcSEcCtD
Vemurafenib—Neuropathy peripheral—Epirubicin—sarcoma	9.2e-05	0.00246	CcSEcCtD
Vemurafenib—Constipation—Etoposide—sarcoma	9.14e-05	0.00244	CcSEcCtD
Vemurafenib—Diarrhoea—Vincristine—sarcoma	9.02e-05	0.00241	CcSEcCtD
Vemurafenib—Photosensitivity reaction—Doxorubicin—sarcoma	8.89e-05	0.00238	CcSEcCtD
Vemurafenib—Nausea—Thiotepa—sarcoma	8.83e-05	0.00236	CcSEcCtD
Vemurafenib—Weight decreased—Doxorubicin—sarcoma	8.82e-05	0.00236	CcSEcCtD
Vemurafenib—Diarrhoea—Mitoxantrone—sarcoma	8.79e-05	0.00235	CcSEcCtD
Vemurafenib—Nausea—Dactinomycin—sarcoma	8.77e-05	0.00234	CcSEcCtD
Vemurafenib—Dizziness—Vincristine—sarcoma	8.72e-05	0.00233	CcSEcCtD
Vemurafenib—Infestation NOS—Doxorubicin—sarcoma	8.69e-05	0.00232	CcSEcCtD
Vemurafenib—Infestation—Doxorubicin—sarcoma	8.69e-05	0.00232	CcSEcCtD
Vemurafenib—Stevens-Johnson syndrome—Doxorubicin—sarcoma	8.61e-05	0.0023	CcSEcCtD
Vemurafenib—Neuropathy peripheral—Doxorubicin—sarcoma	8.52e-05	0.00228	CcSEcCtD
Vemurafenib—Body temperature increased—Etoposide—sarcoma	8.45e-05	0.00226	CcSEcCtD
Vemurafenib—Vomiting—Vincristine—sarcoma	8.39e-05	0.00224	CcSEcCtD
Vemurafenib—ABCG2—lymph node—sarcoma	8.35e-05	0.00595	CbGeAlD
Vemurafenib—Rash—Vincristine—sarcoma	8.32e-05	0.00222	CcSEcCtD
Vemurafenib—Dermatitis—Vincristine—sarcoma	8.31e-05	0.00222	CcSEcCtD
Vemurafenib—Oedema peripheral—Epirubicin—sarcoma	8.3e-05	0.00222	CcSEcCtD
Vemurafenib—Connective tissue disorder—Epirubicin—sarcoma	8.28e-05	0.00221	CcSEcCtD
Vemurafenib—Headache—Vincristine—sarcoma	8.26e-05	0.00221	CcSEcCtD
Vemurafenib—Vomiting—Mitoxantrone—sarcoma	8.17e-05	0.00218	CcSEcCtD
Vemurafenib—Rash—Mitoxantrone—sarcoma	8.1e-05	0.00216	CcSEcCtD
Vemurafenib—Dermatitis—Mitoxantrone—sarcoma	8.09e-05	0.00216	CcSEcCtD
Vemurafenib—Headache—Mitoxantrone—sarcoma	8.05e-05	0.00215	CcSEcCtD
Vemurafenib—Erythema multiforme—Epirubicin—sarcoma	7.97e-05	0.00213	CcSEcCtD
Vemurafenib—CYP2D6—testis—sarcoma	7.9e-05	0.00563	CbGeAlD
Vemurafenib—Eye disorder—Epirubicin—sarcoma	7.88e-05	0.0021	CcSEcCtD
Vemurafenib—Hypersensitivity—Etoposide—sarcoma	7.87e-05	0.0021	CcSEcCtD
Vemurafenib—Nausea—Vincristine—sarcoma	7.83e-05	0.00209	CcSEcCtD
Vemurafenib—Cardiac disorder—Epirubicin—sarcoma	7.82e-05	0.00209	CcSEcCtD
Vemurafenib—Oedema peripheral—Doxorubicin—sarcoma	7.68e-05	0.00205	CcSEcCtD
Vemurafenib—Asthenia—Etoposide—sarcoma	7.66e-05	0.00205	CcSEcCtD
Vemurafenib—Connective tissue disorder—Doxorubicin—sarcoma	7.66e-05	0.00205	CcSEcCtD
Vemurafenib—Angiopathy—Epirubicin—sarcoma	7.65e-05	0.00204	CcSEcCtD
Vemurafenib—Nausea—Mitoxantrone—sarcoma	7.63e-05	0.00204	CcSEcCtD
Vemurafenib—Mediastinal disorder—Epirubicin—sarcoma	7.6e-05	0.00203	CcSEcCtD
Vemurafenib—CYP3A4—liver—sarcoma	7.59e-05	0.0054	CbGeAlD
Vemurafenib—Chills—Epirubicin—sarcoma	7.56e-05	0.00202	CcSEcCtD
Vemurafenib—Pruritus—Etoposide—sarcoma	7.56e-05	0.00202	CcSEcCtD
Vemurafenib—CYP2D6—liver—sarcoma	7.47e-05	0.00532	CbGeAlD
Vemurafenib—Alopecia—Epirubicin—sarcoma	7.45e-05	0.00199	CcSEcCtD
Vemurafenib—Erythema multiforme—Doxorubicin—sarcoma	7.37e-05	0.00197	CcSEcCtD
Vemurafenib—Erythema—Epirubicin—sarcoma	7.34e-05	0.00196	CcSEcCtD
Vemurafenib—Malnutrition—Epirubicin—sarcoma	7.34e-05	0.00196	CcSEcCtD
Vemurafenib—Diarrhoea—Etoposide—sarcoma	7.31e-05	0.00195	CcSEcCtD
Vemurafenib—Eye disorder—Doxorubicin—sarcoma	7.29e-05	0.00195	CcSEcCtD
Vemurafenib—Cardiac disorder—Doxorubicin—sarcoma	7.24e-05	0.00193	CcSEcCtD
Vemurafenib—Dysgeusia—Epirubicin—sarcoma	7.19e-05	0.00192	CcSEcCtD
Vemurafenib—Back pain—Epirubicin—sarcoma	7.1e-05	0.0019	CcSEcCtD
Vemurafenib—Angiopathy—Doxorubicin—sarcoma	7.08e-05	0.00189	CcSEcCtD
Vemurafenib—Dizziness—Etoposide—sarcoma	7.06e-05	0.00189	CcSEcCtD
Vemurafenib—Mediastinal disorder—Doxorubicin—sarcoma	7.03e-05	0.00188	CcSEcCtD
Vemurafenib—Chills—Doxorubicin—sarcoma	7e-05	0.00187	CcSEcCtD
Vemurafenib—Alopecia—Doxorubicin—sarcoma	6.89e-05	0.00184	CcSEcCtD
Vemurafenib—Vomiting—Etoposide—sarcoma	6.79e-05	0.00181	CcSEcCtD
Vemurafenib—Malnutrition—Doxorubicin—sarcoma	6.79e-05	0.00181	CcSEcCtD
Vemurafenib—Erythema—Doxorubicin—sarcoma	6.79e-05	0.00181	CcSEcCtD
Vemurafenib—Rash—Etoposide—sarcoma	6.74e-05	0.0018	CcSEcCtD
Vemurafenib—Dermatitis—Etoposide—sarcoma	6.73e-05	0.0018	CcSEcCtD
Vemurafenib—Headache—Etoposide—sarcoma	6.69e-05	0.00179	CcSEcCtD
Vemurafenib—Dysgeusia—Doxorubicin—sarcoma	6.65e-05	0.00178	CcSEcCtD
Vemurafenib—Back pain—Doxorubicin—sarcoma	6.57e-05	0.00175	CcSEcCtD
Vemurafenib—Cough—Epirubicin—sarcoma	6.4e-05	0.00171	CcSEcCtD
Vemurafenib—Nausea—Etoposide—sarcoma	6.35e-05	0.0017	CcSEcCtD
Vemurafenib—Myalgia—Epirubicin—sarcoma	6.25e-05	0.00167	CcSEcCtD
Vemurafenib—Arthralgia—Epirubicin—sarcoma	6.25e-05	0.00167	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—sarcoma	6.2e-05	0.00166	CcSEcCtD
Vemurafenib—Anaphylactic shock—Epirubicin—sarcoma	5.99e-05	0.0016	CcSEcCtD
Vemurafenib—Infection—Epirubicin—sarcoma	5.95e-05	0.00159	CcSEcCtD
Vemurafenib—Cough—Doxorubicin—sarcoma	5.92e-05	0.00158	CcSEcCtD
Vemurafenib—Nervous system disorder—Epirubicin—sarcoma	5.87e-05	0.00157	CcSEcCtD
Vemurafenib—Skin disorder—Epirubicin—sarcoma	5.82e-05	0.00155	CcSEcCtD
Vemurafenib—Arthralgia—Doxorubicin—sarcoma	5.78e-05	0.00154	CcSEcCtD
Vemurafenib—Myalgia—Doxorubicin—sarcoma	5.78e-05	0.00154	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—sarcoma	5.74e-05	0.00153	CcSEcCtD
Vemurafenib—Hypotension—Epirubicin—sarcoma	5.6e-05	0.0015	CcSEcCtD
Vemurafenib—Anaphylactic shock—Doxorubicin—sarcoma	5.54e-05	0.00148	CcSEcCtD
Vemurafenib—Infection—Doxorubicin—sarcoma	5.5e-05	0.00147	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Epirubicin—sarcoma	5.46e-05	0.00146	CcSEcCtD
Vemurafenib—Nervous system disorder—Doxorubicin—sarcoma	5.43e-05	0.00145	CcSEcCtD
Vemurafenib—Skin disorder—Doxorubicin—sarcoma	5.38e-05	0.00144	CcSEcCtD
Vemurafenib—Decreased appetite—Epirubicin—sarcoma	5.21e-05	0.00139	CcSEcCtD
Vemurafenib—Hypotension—Doxorubicin—sarcoma	5.18e-05	0.00138	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Epirubicin—sarcoma	5.17e-05	0.00138	CcSEcCtD
Vemurafenib—Fatigue—Epirubicin—sarcoma	5.16e-05	0.00138	CcSEcCtD
Vemurafenib—Constipation—Epirubicin—sarcoma	5.12e-05	0.00137	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Doxorubicin—sarcoma	5.05e-05	0.00135	CcSEcCtD
Vemurafenib—Decreased appetite—Doxorubicin—sarcoma	4.82e-05	0.00129	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Doxorubicin—sarcoma	4.78e-05	0.00128	CcSEcCtD
Vemurafenib—Fatigue—Doxorubicin—sarcoma	4.78e-05	0.00128	CcSEcCtD
Vemurafenib—Constipation—Doxorubicin—sarcoma	4.74e-05	0.00127	CcSEcCtD
Vemurafenib—Body temperature increased—Epirubicin—sarcoma	4.73e-05	0.00126	CcSEcCtD
Vemurafenib—Hypersensitivity—Epirubicin—sarcoma	4.41e-05	0.00118	CcSEcCtD
Vemurafenib—Body temperature increased—Doxorubicin—sarcoma	4.38e-05	0.00117	CcSEcCtD
Vemurafenib—Asthenia—Epirubicin—sarcoma	4.3e-05	0.00115	CcSEcCtD
Vemurafenib—Pruritus—Epirubicin—sarcoma	4.24e-05	0.00113	CcSEcCtD
Vemurafenib—Diarrhoea—Epirubicin—sarcoma	4.1e-05	0.00109	CcSEcCtD
Vemurafenib—Hypersensitivity—Doxorubicin—sarcoma	4.08e-05	0.00109	CcSEcCtD
Vemurafenib—Asthenia—Doxorubicin—sarcoma	3.98e-05	0.00106	CcSEcCtD
Vemurafenib—Dizziness—Epirubicin—sarcoma	3.96e-05	0.00106	CcSEcCtD
Vemurafenib—Pruritus—Doxorubicin—sarcoma	3.92e-05	0.00105	CcSEcCtD
Vemurafenib—Vomiting—Epirubicin—sarcoma	3.81e-05	0.00102	CcSEcCtD
Vemurafenib—Diarrhoea—Doxorubicin—sarcoma	3.79e-05	0.00101	CcSEcCtD
Vemurafenib—Rash—Epirubicin—sarcoma	3.78e-05	0.00101	CcSEcCtD
Vemurafenib—Dermatitis—Epirubicin—sarcoma	3.77e-05	0.00101	CcSEcCtD
Vemurafenib—Headache—Epirubicin—sarcoma	3.75e-05	0.001	CcSEcCtD
Vemurafenib—Dizziness—Doxorubicin—sarcoma	3.66e-05	0.000979	CcSEcCtD
Vemurafenib—Nausea—Epirubicin—sarcoma	3.56e-05	0.00095	CcSEcCtD
Vemurafenib—Vomiting—Doxorubicin—sarcoma	3.52e-05	0.000941	CcSEcCtD
Vemurafenib—Rash—Doxorubicin—sarcoma	3.49e-05	0.000933	CcSEcCtD
Vemurafenib—Dermatitis—Doxorubicin—sarcoma	3.49e-05	0.000933	CcSEcCtD
Vemurafenib—Headache—Doxorubicin—sarcoma	3.47e-05	0.000927	CcSEcCtD
Vemurafenib—Nausea—Doxorubicin—sarcoma	3.29e-05	0.000879	CcSEcCtD
Vemurafenib—ABCC1—Disease—NPM1—sarcoma	2.04e-05	0.000284	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by SCF-KIT—HRAS—sarcoma	2.02e-05	0.000282	CbGpPWpGaD
Vemurafenib—RAF1—Integrated Pancreatic Cancer Pathway—MYC—sarcoma	2.02e-05	0.000282	CbGpPWpGaD
Vemurafenib—RAF1—Platelet activation, signaling and aggregation—SRC—sarcoma	2.01e-05	0.00028	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—FOXO1—sarcoma	1.99e-05	0.000278	CbGpPWpGaD
Vemurafenib—RAF1—BDNF signaling pathway—HRAS—sarcoma	1.99e-05	0.000278	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—PDGFRB—sarcoma	1.99e-05	0.000277	CbGpPWpGaD
Vemurafenib—RAF1—Focal Adhesion—EGFR—sarcoma	1.99e-05	0.000277	CbGpPWpGaD
Vemurafenib—RAF1—DAP12 interactions—KRAS—sarcoma	1.99e-05	0.000277	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by FGFR in disease—KRAS—sarcoma	1.99e-05	0.000277	CbGpPWpGaD
Vemurafenib—RAF1—Fc epsilon receptor (FCERI) signaling—KRAS—sarcoma	1.99e-05	0.000277	CbGpPWpGaD
Vemurafenib—RAF1—Integrated Pancreatic Cancer Pathway—EGFR—sarcoma	1.98e-05	0.000276	CbGpPWpGaD
Vemurafenib—RAF1—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—sarcoma	1.97e-05	0.000275	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by EGFR—KRAS—sarcoma	1.97e-05	0.000274	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—PDGFRA—sarcoma	1.96e-05	0.000273	CbGpPWpGaD
Vemurafenib—RAF1—Platelet activation, signaling and aggregation—VEGFA—sarcoma	1.96e-05	0.000273	CbGpPWpGaD
Vemurafenib—BRAF—Signaling by NGF—KRAS—sarcoma	1.95e-05	0.000273	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by EGFR in Cancer—KRAS—sarcoma	1.95e-05	0.000272	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—VEGFC—sarcoma	1.94e-05	0.000271	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by PDGF—KRAS—sarcoma	1.94e-05	0.000271	CbGpPWpGaD
Vemurafenib—RAF1—Downstream signaling of activated FGFR—HRAS—sarcoma	1.94e-05	0.00027	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—FOXO1—sarcoma	1.91e-05	0.000267	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—PDGFRB—sarcoma	1.91e-05	0.000266	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by ERBB4—HRAS—sarcoma	1.91e-05	0.000266	CbGpPWpGaD
Vemurafenib—RAF1—Cytokine Signaling in Immune system—IL2—sarcoma	1.9e-05	0.000265	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—PDGFRA—sarcoma	1.88e-05	0.000262	CbGpPWpGaD
Vemurafenib—RAF1—Integrated Pancreatic Cancer Pathway—KRAS—sarcoma	1.87e-05	0.00026	CbGpPWpGaD
Vemurafenib—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—sarcoma	1.87e-05	0.00026	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—KDR—sarcoma	1.86e-05	0.00026	CbGpPWpGaD
Vemurafenib—RAF1—NGF signalling via TRKA from the plasma membrane—EGFR—sarcoma	1.86e-05	0.00026	CbGpPWpGaD
Vemurafenib—RAF1—MAPK Signaling Pathway—TP53—sarcoma	1.84e-05	0.000257	CbGpPWpGaD
Vemurafenib—RAF1—Insulin Signaling—HRAS—sarcoma	1.83e-05	0.000255	CbGpPWpGaD
Vemurafenib—RAF1—Downstream signal transduction—HRAS—sarcoma	1.82e-05	0.000254	CbGpPWpGaD
Vemurafenib—RAF1—EGF/EGFR Signaling Pathway—HRAS—sarcoma	1.81e-05	0.000253	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by FGFR—HRAS—sarcoma	1.81e-05	0.000253	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by ERBB2—HRAS—sarcoma	1.8e-05	0.000251	CbGpPWpGaD
Vemurafenib—RAF1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—sarcoma	1.8e-05	0.000251	CbGpPWpGaD
Vemurafenib—RAF1—DAP12 signaling—HRAS—sarcoma	1.79e-05	0.00025	CbGpPWpGaD
Vemurafenib—RAF1—Disease—ENO2—sarcoma	1.78e-05	0.000248	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—ENO2—sarcoma	1.76e-05	0.000246	CbGpPWpGaD
Vemurafenib—RAF1—NGF signalling via TRKA from the plasma membrane—KRAS—sarcoma	1.76e-05	0.000245	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—CXCR4—sarcoma	1.72e-05	0.00024	CbGpPWpGaD
Vemurafenib—RAF1—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—sarcoma	1.7e-05	0.000237	CbGpPWpGaD
Vemurafenib—BRAF—Neuronal System—HRAS—sarcoma	1.69e-05	0.000236	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by FGFR in disease—HRAS—sarcoma	1.69e-05	0.000235	CbGpPWpGaD
Vemurafenib—RAF1—Fc epsilon receptor (FCERI) signaling—HRAS—sarcoma	1.69e-05	0.000235	CbGpPWpGaD
Vemurafenib—RAF1—DAP12 interactions—HRAS—sarcoma	1.69e-05	0.000235	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—PLCG1—sarcoma	1.68e-05	0.000234	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by EGFR—HRAS—sarcoma	1.67e-05	0.000233	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—PTPRC—sarcoma	1.67e-05	0.000233	CbGpPWpGaD
Vemurafenib—BRAF—Signaling by NGF—HRAS—sarcoma	1.66e-05	0.000232	CbGpPWpGaD
Vemurafenib—RAF1—Integrated Pancreatic Cancer Pathway—TP53—sarcoma	1.66e-05	0.000232	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by EGFR in Cancer—HRAS—sarcoma	1.66e-05	0.000231	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by PDGF—HRAS—sarcoma	1.65e-05	0.00023	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—CREB1—sarcoma	1.64e-05	0.000228	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—PLCG1—sarcoma	1.63e-05	0.000228	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by NGF—SRC—sarcoma	1.63e-05	0.000228	CbGpPWpGaD
Vemurafenib—RAF1—Cytokine Signaling in Immune system—NRAS—sarcoma	1.6e-05	0.000223	CbGpPWpGaD
Vemurafenib—RAF1—Focal Adhesion—HRAS—sarcoma	1.59e-05	0.000222	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—TLE1—sarcoma	1.59e-05	0.000222	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by NGF—NRAS—sarcoma	1.57e-05	0.000219	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—FLT1—sarcoma	1.55e-05	0.000217	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—ATF1—sarcoma	1.55e-05	0.000217	CbGpPWpGaD
Vemurafenib—BRAF—Disease—FOXO1—sarcoma	1.55e-05	0.000216	CbGpPWpGaD
Vemurafenib—BRAF—Disease—PDGFRB—sarcoma	1.54e-05	0.000215	CbGpPWpGaD
Vemurafenib—RAF1—Transmission across Chemical Synapses—HRAS—sarcoma	1.53e-05	0.000213	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—PLCG1—sarcoma	1.53e-05	0.000213	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—MMP2—sarcoma	1.52e-05	0.000212	CbGpPWpGaD
Vemurafenib—BRAF—Disease—PDGFRA—sarcoma	1.52e-05	0.000212	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—KIT—sarcoma	1.52e-05	0.000212	CbGpPWpGaD
Vemurafenib—RAF1—Disease—PLCG1—sarcoma	1.51e-05	0.00021	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—PLCG1—sarcoma	1.5e-05	0.000209	CbGpPWpGaD
Vemurafenib—RAF1—NGF signalling via TRKA from the plasma membrane—HRAS—sarcoma	1.49e-05	0.000208	CbGpPWpGaD
Vemurafenib—RAF1—Axon guidance—SRC—sarcoma	1.48e-05	0.000206	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—ENO2—sarcoma	1.48e-05	0.000206	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—CXCR4—sarcoma	1.47e-05	0.000205	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—HBA1—sarcoma	1.47e-05	0.000205	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—KIT—sarcoma	1.46e-05	0.000203	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—ATF1—sarcoma	1.45e-05	0.000202	CbGpPWpGaD
Vemurafenib—RAF1—Disease—CXCR4—sarcoma	1.45e-05	0.000202	CbGpPWpGaD
Vemurafenib—RAF1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—sarcoma	1.44e-05	0.000201	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—CREB1—sarcoma	1.44e-05	0.000201	CbGpPWpGaD
Vemurafenib—RAF1—Axon guidance—VEGFA—sarcoma	1.44e-05	0.000201	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—CXCR4—sarcoma	1.44e-05	0.0002	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by NGF—EGFR—sarcoma	1.43e-05	0.0002	CbGpPWpGaD
Vemurafenib—RAF1—Axon guidance—NRAS—sarcoma	1.42e-05	0.000198	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—CREB1—sarcoma	1.39e-05	0.000193	CbGpPWpGaD
Vemurafenib—RAF1—Cytokine Signaling in Immune system—KRAS—sarcoma	1.38e-05	0.000192	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by NGF—KRAS—sarcoma	1.35e-05	0.000189	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—VEGFC—sarcoma	1.34e-05	0.000188	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—ENO2—sarcoma	1.3e-05	0.000181	CbGpPWpGaD
Vemurafenib—RAF1—Axon guidance—EGFR—sarcoma	1.3e-05	0.000181	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—HBA1—sarcoma	1.29e-05	0.00018	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—PLCG1—sarcoma	1.25e-05	0.000175	CbGpPWpGaD
Vemurafenib—ALB—Platelet activation, signaling and aggregation—IL2—sarcoma	1.24e-05	0.000173	CbGpPWpGaD
Vemurafenib—RAF1—Axon guidance—KRAS—sarcoma	1.22e-05	0.000171	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—MDM2—sarcoma	1.19e-05	0.000167	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—IL2—sarcoma	1.19e-05	0.000165	CbGpPWpGaD
Vemurafenib—BRAF—Disease—KIT—sarcoma	1.18e-05	0.000164	CbGpPWpGaD
Vemurafenib—RAF1—Neuronal System—HRAS—sarcoma	1.17e-05	0.000164	CbGpPWpGaD
Vemurafenib—RAF1—Cytokine Signaling in Immune system—HRAS—sarcoma	1.17e-05	0.000163	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—CTNNB1—sarcoma	1.17e-05	0.000163	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—FOXO1—sarcoma	1.16e-05	0.000162	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—PDGFRB—sarcoma	1.16e-05	0.000161	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by NGF—HRAS—sarcoma	1.15e-05	0.00016	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—MDM2—sarcoma	1.15e-05	0.00016	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—PDGFRA—sarcoma	1.14e-05	0.000159	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—IGF1R—sarcoma	1.14e-05	0.000159	CbGpPWpGaD
Vemurafenib—BRAF—Disease—CREB1—sarcoma	1.12e-05	0.000157	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—PLCG1—sarcoma	1.1e-05	0.000154	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—FOXO1—sarcoma	1.08e-05	0.000151	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—PDGFRB—sarcoma	1.08e-05	0.000151	CbGpPWpGaD
Vemurafenib—ALB—Platelet activation, signaling and aggregation—SRC—sarcoma	1.08e-05	0.000151	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—FLT1—sarcoma	1.08e-05	0.00015	CbGpPWpGaD
Vemurafenib—RAF1—Disease—FOXO1—sarcoma	1.07e-05	0.000149	CbGpPWpGaD
Vemurafenib—RAF1—Disease—PDGFRB—sarcoma	1.07e-05	0.000149	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—PDGFRA—sarcoma	1.06e-05	0.000148	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—FOXO1—sarcoma	1.06e-05	0.000148	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—PDGFRB—sarcoma	1.06e-05	0.000148	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—PLCG1—sarcoma	1.06e-05	0.000147	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—SRC—sarcoma	1.05e-05	0.000147	CbGpPWpGaD
Vemurafenib—ALB—Platelet activation, signaling and aggregation—VEGFA—sarcoma	1.05e-05	0.000147	CbGpPWpGaD
Vemurafenib—RAF1—Disease—PDGFRA—sarcoma	1.05e-05	0.000147	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—PDGFRA—sarcoma	1.04e-05	0.000145	CbGpPWpGaD
Vemurafenib—RAF1—Axon guidance—HRAS—sarcoma	1.04e-05	0.000145	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—JUN—sarcoma	1.04e-05	0.000145	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—SRC—sarcoma	1.03e-05	0.000144	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—CTNNB1—sarcoma	1.03e-05	0.000144	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—VEGFA—sarcoma	1.03e-05	0.000143	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CXCR4—sarcoma	1.02e-05	0.000142	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—NRAS—sarcoma	1.01e-05	0.000142	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—VEGFA—sarcoma	1.01e-05	0.000141	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—ATF1—sarcoma	1e-05	0.00014	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—NRAS—sarcoma	9.95e-06	0.000139	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—SRC—sarcoma	9.32e-06	0.00013	CbGpPWpGaD
Vemurafenib—BRAF—Disease—MDM2—sarcoma	9.29e-06	0.000129	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—EGFR—sarcoma	9.25e-06	0.000129	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—CREB1—sarcoma	9.21e-06	0.000128	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—KDR—sarcoma	8.96e-06	0.000125	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—NRAS—sarcoma	8.96e-06	0.000125	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—SRC—sarcoma	8.95e-06	0.000125	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—KIT—sarcoma	8.84e-06	0.000123	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—KRAS—sarcoma	8.73e-06	0.000122	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—NRAS—sarcoma	8.61e-06	0.00012	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—KRAS—sarcoma	8.57e-06	0.000119	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—CREB1—sarcoma	8.41e-06	0.000117	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—KIT—sarcoma	8.26e-06	0.000115	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—EGFR—sarcoma	8.17e-06	0.000114	CbGpPWpGaD
Vemurafenib—RAF1—Disease—KIT—sarcoma	8.16e-06	0.000114	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—KIT—sarcoma	8.09e-06	0.000113	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—ENO2—sarcoma	8.02e-06	0.000112	CbGpPWpGaD
Vemurafenib—BRAF—Disease—CTNNB1—sarcoma	8.01e-06	0.000112	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—HBA1—sarcoma	7.97e-06	0.000111	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—IGF1R—sarcoma	7.88e-06	0.00011	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—CREB1—sarcoma	7.86e-06	0.00011	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—EGFR—sarcoma	7.84e-06	0.000109	CbGpPWpGaD
Vemurafenib—RAF1—Disease—CREB1—sarcoma	7.77e-06	0.000108	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—KRAS—sarcoma	7.71e-06	0.000108	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—CREB1—sarcoma	7.7e-06	0.000107	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—TP53—sarcoma	7.61e-06	0.000106	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—FOXO1—sarcoma	7.5e-06	0.000105	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—PDGFRB—sarcoma	7.48e-06	0.000104	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—HRAS—sarcoma	7.42e-06	0.000104	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—KRAS—sarcoma	7.41e-06	0.000103	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—PDGFRA—sarcoma	7.37e-06	0.000103	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—HRAS—sarcoma	7.28e-06	0.000102	CbGpPWpGaD
Vemurafenib—BRAF—Disease—SRC—sarcoma	7.24e-06	0.000101	CbGpPWpGaD
Vemurafenib—BRAF—Disease—NRAS—sarcoma	6.97e-06	9.71e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—MDM2—sarcoma	6.96e-06	9.7e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—IL2—sarcoma	6.81e-06	9.49e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—PLCG1—sarcoma	6.8e-06	9.48e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—ENO2—sarcoma	6.62e-06	9.23e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—HBA1—sarcoma	6.58e-06	9.17e-05	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—HRAS—sarcoma	6.56e-06	9.14e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—MDM2—sarcoma	6.5e-06	9.07e-05	CbGpPWpGaD
Vemurafenib—BRAF—Disease—MYC—sarcoma	6.49e-06	9.05e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—MDM2—sarcoma	6.43e-06	8.96e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—IL2—sarcoma	6.38e-06	8.9e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—MDM2—sarcoma	6.37e-06	8.88e-05	CbGpPWpGaD
Vemurafenib—BRAF—Disease—EGFR—sarcoma	6.35e-06	8.85e-05	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—HRAS—sarcoma	6.3e-06	8.78e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—IL2—sarcoma	6.22e-06	8.67e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—KDR—sarcoma	6.2e-06	8.65e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—JUN—sarcoma	6.05e-06	8.43e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—CTNNB1—sarcoma	6e-06	8.37e-05	CbGpPWpGaD
Vemurafenib—BRAF—Disease—KRAS—sarcoma	6e-06	8.36e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—IL2—sarcoma	5.81e-06	8.1e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—KIT—sarcoma	5.71e-06	7.97e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—NRAS—sarcoma	5.71e-06	7.97e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—CCND1—sarcoma	5.66e-06	7.9e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—JUN—sarcoma	5.65e-06	7.88e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—PLCG1—sarcoma	5.62e-06	7.83e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—CTNNB1—sarcoma	5.61e-06	7.82e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—ENO2—sarcoma	5.61e-06	7.82e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—HBA1—sarcoma	5.57e-06	7.77e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—SRC—sarcoma	5.57e-06	7.77e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—CTNNB1—sarcoma	5.54e-06	7.73e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—CTNNB1—sarcoma	5.49e-06	7.66e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CREB1—sarcoma	5.44e-06	7.58e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—SRC—sarcoma	5.43e-06	7.57e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—VEGFA—sarcoma	5.42e-06	7.56e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—NRAS—sarcoma	5.36e-06	7.47e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—NRAS—sarcoma	5.22e-06	7.28e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—EGFR—sarcoma	5.2e-06	7.26e-05	CbGpPWpGaD
Vemurafenib—BRAF—Disease—HRAS—sarcoma	5.1e-06	7.11e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—SRC—sarcoma	5.07e-06	7.07e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—SRC—sarcoma	5.01e-06	6.99e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—SRC—sarcoma	4.97e-06	6.92e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—VEGFA—sarcoma	4.94e-06	6.89e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—KRAS—sarcoma	4.92e-06	6.86e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—NRAS—sarcoma	4.88e-06	6.8e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—NRAS—sarcoma	4.82e-06	6.72e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—NRAS—sarcoma	4.78e-06	6.66e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PLCG1—sarcoma	4.76e-06	6.63e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—EGFR—sarcoma	4.76e-06	6.63e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—KRAS—sarcoma	4.61e-06	6.43e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—MYC—sarcoma	4.54e-06	6.34e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—MDM2—sarcoma	4.5e-06	6.27e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—KRAS—sarcoma	4.49e-06	6.26e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—MYC—sarcoma	4.49e-06	6.26e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—MYC—sarcoma	4.45e-06	6.2e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—EGFR—sarcoma	4.44e-06	6.2e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—EGFR—sarcoma	4.39e-06	6.12e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—EGFR—sarcoma	4.35e-06	6.07e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—ENO2—sarcoma	4.33e-06	6.03e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—HBA1—sarcoma	4.3e-06	6e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—KRAS—sarcoma	4.2e-06	5.85e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—HRAS—sarcoma	4.18e-06	5.83e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—KRAS—sarcoma	4.15e-06	5.78e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—KRAS—sarcoma	4.11e-06	5.73e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—TP53—sarcoma	4.1e-06	5.72e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—IL2—sarcoma	4.02e-06	5.61e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—HRAS—sarcoma	3.92e-06	5.47e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CCND1—sarcoma	3.92e-06	5.46e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—JUN—sarcoma	3.91e-06	5.45e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CTNNB1—sarcoma	3.88e-06	5.41e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—HRAS—sarcoma	3.82e-06	5.32e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—TP53—sarcoma	3.73e-06	5.2e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PLCG1—sarcoma	3.67e-06	5.12e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—HRAS—sarcoma	3.57e-06	4.98e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—HRAS—sarcoma	3.53e-06	4.92e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—SRC—sarcoma	3.51e-06	4.89e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—HRAS—sarcoma	3.49e-06	4.87e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—VEGFA—sarcoma	3.42e-06	4.76e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—NRAS—sarcoma	3.37e-06	4.71e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—MYC—sarcoma	3.14e-06	4.38e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—EGFR—sarcoma	3.07e-06	4.29e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—KRAS—sarcoma	2.9e-06	4.05e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—TP53—sarcoma	2.58e-06	3.6e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—HRAS—sarcoma	2.47e-06	3.44e-05	CbGpPWpGaD
